CytomX Therapeutics (NASDAQ:CTMX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of CytomX Therapeutics (NASDAQ:CTMX) from a sell rating to a hold rating in a research report released on Saturday,Wall Street Zen reports.

A number of other brokerages also recently issued reports on CTMX. Zacks Research downgraded shares of CytomX Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. JPMorgan Chase & Co. decreased their target price on shares of CytomX Therapeutics from $12.00 to $11.00 and set an “overweight” rating for the company in a research report on Thursday, August 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of CytomX Therapeutics in a research report on Tuesday, October 13th. Weiss Ratings restated a “sell (d)” rating on shares of CytomX Therapeutics in a research note on Friday, September 11th. Finally, Guggenheim cut their price target on shares of CytomX Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $12.00.

CytomX Therapeutics Price Performance

Shares of CTMX stock opened at $1.98 on Friday. The stock’s 50-day moving average is $2.69 and its 200 day moving average is $3.80. CytomX Therapeutics has a 1-year low of $1.95 and a 1-year high of $8.21. The company has a market cap of $431.44 million, a P/E ratio of -3.96 and a beta of 2.23.

CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Thursday, November 5th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). The firm had revenue of $1.69 million during the quarter, compared to the consensus estimate of $10.38 million. CytomX Therapeutics had a negative return on equity of 38.46% and a negative net margin of 435.21%. On average, analysts anticipate that CytomX Therapeutics will post -0.40 EPS for the current year.

Institutional Investors Weigh In On CytomX Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Almanack Investment Partners LLC. purchased a new stake in shares of CytomX Therapeutics during the third quarter worth about $30,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of CytomX Therapeutics in the 3rd quarter valued at approximately $30,000. Integrated Wealth Concepts LLC purchased a new position in shares of CytomX Therapeutics in the 2nd quarter valued at approximately $47,000. Nierenberg Investment Management Company LLC purchased a new position in shares of CytomX Therapeutics in the 2nd quarter valued at approximately $47,081. Finally, Lido Advisors LLC acquired a new stake in CytomX Therapeutics in the 1st quarter worth approximately $49,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing cancer medicines designed to be activated selectively within the tumor microenvironment. The company’s approach is intended to improve the precision of treatment by limiting activity in healthy tissues while enabling therapeutic effects at tumor sites.

CytomX’s research is based on its Probody therapeutic platform, which uses molecular masking and tumor-associated protease activity to conditionally activate antibody-based medicines.